Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

What Doctors Say About
Test Before Treat™

What critical concern could compel these CLL Experts from some of the top research centers around the world, to come before our cameras and speak so urgently to you, our readers? The answer: Test Before Treat™! The truth is that critical tests which can predict which patients will do well on or fail certain medications and should be done before each and every treatment decision, are often not being done… or are being done and the results are ignored. Take our patients’ stories to heart. Print out our one-pager. Share it with your doctor. Smart Patients Get Smart Care™.

As new and better treatments are developed to treat Chronic Lymphocytic Leukemia, and Small Lymphocytic Lymphoma (CLL / SLL), testing for subtypes of the disease is becoming more important for prognosis and selection of the best treatment options.
At the American Society of Hematology’s (ASH) 2020 conference, there was research on looking at the genome of CLL and how different genetic markers might have predictive and value. Dr. Brian Koffman, Chief Medical Officer and Executive Vice President of CLL Society, interviewed Dr. Adrian Wiestner, a senior investigator at
CLL Society On Demand Ed Forum: ASH 2020 Comes to You – Session 1: Encouraging Updates on Drugs in Development + the Sad State of Test Before Treat Recorded Thursday, February 4, 2021 Continue to Session 2: CLL Treatments: Chemotherapy, Immunotherapy, and Targeted Agents CLL Society Resources Download